Thank you for sharing!

Your article was successfully shared with the contacts you provided.
U.S. Federal Trade Commission building. October 16, 2012. Photo by Diego M. Radzinschi/THE NATIONAL LAW JOURNAL.U.S. Federal Trade Commission building. October 16, 2012. Photo by Diego M. Radzinschi/THE NATIONAL LAW JOURNAL. ()

Over the past year, the pharmaceutical industry saw more than 300 deals worth in excess of $400 billion. The frenzy of activity presented antitrust agencies with numerous transactions that resulted in settlements to remedy concerns about their impact on competition.

Both the Federal Trade Commission and the U.S. Department of Justice have the authority to review pharmaceutical transactions that exceed the $78.2 million Hart-Scott-Rodino filing threshold. Notably, however, the pharmaceutical industry is one of the industries where it is most clear that one agency — the FTC — is responsible for investigating the proposed transactions. Beyond investigating Hart-Scott-Rodino-reportable pharmaceutical transactions, the FTC has shown a willingness to challenge even small, nonreportable pharmaceutical ­transactions.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.